Participants with inappropriate therapies by final study diagnosis among cases with discordance in validated local diagnosis
| Therapy class . | Final study diagnosis . | |||||||
|---|---|---|---|---|---|---|---|---|
| MDS (n = 54) . | MDS/MPN overlap (n = 17) . | ICUS (n = 17) . | AML blasts∗ (n = 3) . | Other AML (n = 0) . | Other malignancy (n = 3) . | Other (n = 1) . | Total (n = 95) . | |
| Any inappropriate therapy | 3 | 2 | 1 | 1 | - | 0 | 0 | 7 |
| Antineoplastic agent† | 2 | 1 | 1 | 1 | 0 | 0 | 0 | 5 |
| Hypomethylating agent | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 1 |
| Other antineoplastic agent | 2 | 1 | 0 | 1 | 0 | 0 | 0 | 4 |
| Corticosteroids for systemic use† | 3 | 1 | 0 | 0 | 0 | 0 | 0 | 4 |
| Immune sera and immunoglobulins† | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 2 |
| Immunosuppressants† | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 3 |
| Therapy class . | Final study diagnosis . | |||||||
|---|---|---|---|---|---|---|---|---|
| MDS (n = 54) . | MDS/MPN overlap (n = 17) . | ICUS (n = 17) . | AML blasts∗ (n = 3) . | Other AML (n = 0) . | Other malignancy (n = 3) . | Other (n = 1) . | Total (n = 95) . | |
| Any inappropriate therapy | 3 | 2 | 1 | 1 | - | 0 | 0 | 7 |
| Antineoplastic agent† | 2 | 1 | 1 | 1 | 0 | 0 | 0 | 5 |
| Hypomethylating agent | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 1 |
| Other antineoplastic agent | 2 | 1 | 0 | 1 | 0 | 0 | 0 | 4 |
| Corticosteroids for systemic use† | 3 | 1 | 0 | 0 | 0 | 0 | 0 | 4 |
| Immune sera and immunoglobulins† | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 2 |
| Immunosuppressants† | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 3 |
The number of participants with the given therapy received by disease group per final central study assignment is reported in this table.
Hypomethylating agents include any azacitidine or decitabine reported. Participants can receive multiple therapies of different classes; therefore, the number of participants receiving individual therapies may not sum to the total number of participants receiving therapy.
n, the number of participants with therapy reviews in each disease group with local discordance in assignment after correcting for any coding errors.
AML with <30% blasts without core binding factor or acute promyelocytic leukemia.
Therapy classes based on the WHO drug Anatomical Therapeutic Chemical Level 2 classification.